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Abstract: Background. Thyroglobulin measurement in the
washout of the needle used in ﬁne-needle aspiration cytology
(FNAC) has been proposed for the early detection of lymph
node metastasis both in patients with or without serum thyro-
globulin antibodies; however, up to now, there have been no
reports that recombinant human thyrotropin (rhTSH) stimulation
modiﬁes thyroglobulin measurement in lymph node aspirates.
Methods. We described, after rhTSH stimulation, the
switching from undetectable to detectable levels of thyroglobu-
lin in ﬁne-needle aspiration ﬂuid from a suspected metastatic
lymph node in 2 patients.
Results. We hypothesized that thyroglobulin levels in the
lymph node increased after rhTSH stimulation. The excess thy-
roglobulin saturates all thyroglobulin antibody binding sites
and becomes detectable, explaining why it was undetectable
when TSH was suppressed.
Conclusion. On the basis of our experience, we suggest
submitting to thyroglobulin measurement in the washout of the
needle used in FNAC all patients with detectable serum thyro-
globulin antibody after rhTSH stimulation. VC 2011 Wiley Periodi-
cals, Inc. Head Neck 00: 000–000, 2011
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Thyroid carcinoma is the most common endocrine
malignancy. Nearly 60% to 80% of new diagnoses are
papillary carcinomas with excellent long-term progno-
sis, even though recurrences and/or metastasis mainly
to cervical lymph nodes have been reported.1 The fol-
low-up after thyroidectomy and radioiodine ablation
(when appropriate) is based on basal and thyrotropin-
stimulated serum thyroglobulin measurement associ-
ated with neck ultrasound evaluation.2,3 Serum thyro-
globulin measurement is the most sensitive and speciﬁc
marker of differentiated thyroid cancer. Elevated con-
centrations of serum thyroglobulin are associated with
the presence of residual or metastatic thyroid tissue.
Nevertheless, thyroglobulin measurement does not
localize neoplastic foci and, moreover, it is seriously
affected by the presence of serum thyroglobulin anti-
bodies, which may mask the presence of a recurrent or
persistent thyroid carcinoma.4 Although ﬁne-needle
aspiration cytology (FNAC) represents an essential tool
for detecting cervical metastasis, this technique is lim-
ited by 6% to 8% false-negative results.5–9 Thyroglobu-
lin measurement in ﬁne-needle aspiration ﬂuid has
been proposed for the early detection of lymph node
metastasis both in patients with and without serum
thyroglobulin antibodies.10–16
In a patient with high levels of serum thyro-
globulin antibodies, we accidentally observed, after
recombinant human thyrotropin (rhTSH) stimulation,
the switching from undetectable to detectable levels
of thyroglobulin in ﬁne-needle aspiration ﬂuid from a
suspected metastatic lymph node. Once the ﬁrst
patient was identiﬁed, we identiﬁed another case
with a high level of serum thyroglobulin antibodies in
which the thyroglobulin obtained from a lymph node
switched from undetectable to detectable after
recombinant thyroid-stimulating hormone.
PATIENTS AND METHODS
Serum thyroid-stimulating hormone (TSH), free thy-
roxine (fT4), thyroglobulin and antibodies antithyro-
globulin were measured using a chemiluminescent
assay by an automated analyzer (Immulite 2000,
DPC Cirrus, Los Angeles, CA).
The thyroglobulin assay had a functional sensitiv-
ity of 0.9 ng/mL with an analytical sensitivity of 0.2
ng/mL. The interassay variability of the thyroglobulin
assay in our laboratory was 3.9%.
Thyroglobulin antibodies were considered negative
when less than 20 IU/mL. The normal range for TSH
and fT4 were 0.4 to 4.5 mIU/L and 7 to 18 pg/mL,
respectively.
Correspondence to: C. Cappelli
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FNAC specimens were obtained by 25-gauge nee-
dle for capillarity under ultrasound guidance; 2
passes were performed with 2 different needles, and
all the samples were performed by the same endocri-
nologist. The needles were washed with 0.5 mL of
normal saline and collected in 2 tubes. The thyroglo-
bulin values were evaluated without considering the
dilution. Before the FNAC procedure, serum samples
for thyroglobulin and thyroglobulin antibodies were
obtained.
CASE REPORTS
Patient 1 was a 53-year-old white woman who under-
went total thyroidectomy for multinodular goiter. The
histology evidenced a unifocal classical papillary car-
cinoma in the right lobe (diameter 11 mm). The
patient was on suppressive therapy with levothyrox-
ine (125 mcg/daily); 2 weeks before radioiodine abla-
tion, an ultrasound investigation evidenced a cervical
lymph node (diameter 6 mm) suspected for metastasis
in the right side of the neck. The patient underwent a
serum assay for thyroglobulin, thyroglobulin antibod-
ies, and thyroglobulin measurement in the washout
of the needle used for the lymph node aspiration (Ta-
ble 1). Serum thyroglobulin and thyroglobulin on ﬁne-
needle aspiration ﬂuid were both undetectable. Seven
days later, she underwent thyroid ablation with
rhTSH stimulation. The patient received 1 injection
of rhTSH (0.9 mg intramuscularly, Thyrogen; Gen-
zyme Therapeutics, Cambrige, MA) for 2 consecutive
days, followed by the therapeutic dose (50 mCi) of 131I
24 hours after the last injection, and by a posttherapy
whole-body scintigraphy (WBS) 72 hours after 131I
treatments. Serum samples for TSH, thyroglobulin,
and thyroglobulin antibodies measurement were col-
lected 3 days after the last injection of rhTSH (Table
1). The WBS showed high radioiodine uptake in the
thyroid bed, compatible with thyroid remnants, and
doubtful uptake in the right neck side where an
ultrasound scan showed the suspected lymph node,
which was (re)submitted to cytology and to thyroglo-
bulin on ﬁne-needle aspiration ﬂuid evaluation 2 days
later. The cytological sample was suggestive of metas-
tases and thyroglobulin was detectable (7.1 ng/mL).
Patient 2 was a 60-year-old white woman affected
by Hashimoto thyroiditis and underwent surgery for
suspected papillary thyroid carcinoma at cytologic
evaluation. The histology conﬁrmed the presence of a
classic papillary carcinoma (diameter 8.3 mm) in the
right lobe of the gland and a microcarcinoma (0.4
mm) in the left lobe. She was on suppressive therapy
with levothyroxine (150 mcg/daily). A neck ultrasound
performed 4 months after surgery showed in the right
side of the neck (level III) a lymph node (diameter 8
mm) suspected of recurrence that underwent thyro-
globulin evaluation on ﬁne-needle aspiration ﬂuid;
thyroglobulin was undetectable. Laboratory ﬁndings
are reported in Table 1. Ten days later, the patient
underwent thyroid ablation with rhTSH stimulation,
as described above. Serum samples for TSH, thyroglo-
bulin, and thyroglobulin antibodies were collected 3
days after the last injection of rhTSH stimulation (Ta-
ble 1). The WBS showed mild radioiodine uptake in
the thyroid bed, compatible with thyroid remnants,
and uptake in the right side of the neck where an
ultrasound showed the suspected lymph node. Before
the administration of therapeutic 131I dose (50 mCi),
the suspected lymph node was subjected to thyroglo-
bulin evaluation on ﬁne-needle aspiration ﬂuid again.
Thyroglobulin assay was 9.2 ng/mL.
Follow-up. Patient 1 (follow-up period 37 months) is
on suppressive therapy. She was resubmitted to I131
(50 mCi) in levothyroxine withdrawal after 1 year.
The WBS was negative for recurrences. Serum thyro-
globulin was undetectable and thyroglobulin antibod-
ies were 303 IU/mL.
Patient 2 (follow-up period 29 months) is on sup-
pressive therapy. She was administered I131 (100
mCi) in levothyroxine withdrawal. The WBS showed
the persistence of iodine uptake in the right side of
the neck, and an ultrasound conﬁrmed the presence
of the suspected lymph node. Serum thyroglobulin
was undetectable and thyroglobulin antibodies were
201 IU/mL.
DISCUSSION
It is well established that serum thyroglobulin mea-
surement is a main tool for the early diagnosis of pap-
illary thyroid cancer recurrence or metastasis, both in
patients in whom TSH levels are obtained with levo-
thyroxine withdrawal or after exogenous TSH stimu-
lation.2,3 The major limitation of this diagnostic
procedure is the presence of detectable serum thyro-
globulin antibodies, which may interfere with the se-
rum thyroglobulin assay, ranging from false-positive
to false-negative results.17–19
Thyroglobulin measurement in lymph node aspi-
rates was ﬁrst described by Pacini et al9 in 1992 to
increase the diagnostic sensitivity in identifying me-
tastasis from thyroid carcinomas in cervical lymph
nodes. Since then, many other authors have adopted
Table 1. Serum and Tg-FNAC assays before and after
rhTSH stimulation.









TSH, mlU/L 0.002 64.3 0.003 58.9
fT4, pg/mL 10.3 11.6 17.1 17.8
Serum TgAb, IU/mL 321 298 176 192
Serum Tg, ng/mL <1 <1 <1 <1
Tg-FNAC, ng/mL <1 7.1 <1 9.2
Abbreviations: Tg-FNAC, thyroglobulin ﬁne-needle aspiration cytology; rhTSH,
recombinant thyroid-stimulating hormone; fT4, free thyroxine; TgAb, thyroglobulin
antibody.
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this procedure with signiﬁcant results.14,20,21
Recently, a large retrospective study by Snozek et al22
showed a 100% sensitivity and a 96% speciﬁcity in
detecting recurrences adopting a thyroglobulin cutoff
in the washout of the needle of 1 ng/mL. Similar
results were also obtained in non-thyroidectomy
patients with lymph nodes metastasis.11–13 The pres-
ence of serum thyroglobulin antibodies seems not to
affect the results of this procedure.
In fact, Baskin16 reported in a small number of
patients that there were no difference in terms of
sensibility and speciﬁcity in detecting lymph node
metastasis between patients with or without serum
thyroglobulin antibodies. Moreover, Boi et al13 found
high thyroglobulin levels in ﬁne-needle aspiration
ﬂuid in all histologically proven metastases, inde-
pendently of the serum thyroglobulin antibodies. Dif-
ferently, we describe 2 patients with detectable serum
thyroglobulin antibodies and suspected lymph node
metastasis in whom thyroglobulin levels in lymph
node aspirates became detectable after rhTSH stimu-
lation. These observations were not due to the serum
thyroglobulin antibody titers as they did not differ
substantially in the 2 patients before and after rhTSH
stimulation.
It has been demonstrated that thyroglobulin
antibodies are found in ﬁne-needle aspiration wash-
out ﬂuid from metastatic lymph nodes in at least
one-quarter of patients with detectable serum thyro-
globulin antibodies.13 For these reasons, it is possi-
ble that thyroglobulin antibodies in metastatic
lymph nodes may fully prevent the detection of thy-
roglobulin in ﬁne-needle washout ﬂuid. One possible
and intriguing explanation for this rare phenomenon
could be that the exceedingly elevated thyroglobulin
antibody concentration in the lymph node saturates
all the thyroglobulin. Unfortunately, we did not ana-
lyze thyroglobulin antibody concentration in ﬁne-
needle washout ﬂuid of our patients; however, we
can hypothesize that thyroglobulin levels in the
lymph node increased after rhTSH stimulation. The
excess thyroglobulin saturates all thyroglobulin anti-
bodies binding sites and becomes detectable, explain-
ing why it was undetectable when TSH was
suppressed.
We must underline the potential limitations of
these case reports: ﬁrst, the absence of histological
conﬁrmation of the suspected lymph nodes metasta-
sis, because neither of the patients underwent sur-
gery; and second, possible sampling error of the
lymph nodes by the operator.
Even if the 2 lymph nodes submitted to ﬁne-nee-
dle aspiration were ‘‘quite small’’ (6 and 8 mm in di-
ameter, respectively), it should be underlined that the
development of technology, particularly the ultra-
sound and probe, makes it possible to successfully
undergo ﬁne-needle cytology even in lesions of just 1
millimeter in diameter.23 In our patients, the samples
were obtained by ultrasound guidance, well visualiz-
ing the needle in the lymph nodes core by a well-
trained and experienced endocrinologist (C. Cap-
pelli)24–27; for this reason we can reasonably exclude
any sample error. Moreover, the 2 suspected lymph
nodes showed ultrasound features (cystic appearance,
loss of hilum, and hyperechoic punctuation) well
known to be associated with metastasis.28,29
However, owing to the lack of histological data,
we can only speculate about the presence of lymph
node recurrences, even though our hypothesis is rein-
forced by ultrasound features of the lymph nodes and
moreover by the presence of thyroglobulin in needle
washout. Also, the results of WBS are in agreement
with our idea.
In conclusion, we report 2 patients with detectable
serum thyroglobulin antibodies in whom thyroglobu-
lin measurements in washout ﬂuid of ﬁne-needle cyto-
logical aspirate of suspected metastatic lymph nodes
became detectable only after rhTSH stimulation.
Additional studies with larger numbers of patients
are needed to conﬁrm our observation.
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